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Abstract
Background: Coronary plaque rupture may result from localised over expression of matrix
metalloproteinases (MMPs) within the plaque by infiltrating monocyte – macrophages. As MMP
expression can be promoted by the modified lipoproteins, oxidative stress and hyperglycaemia that
characterises Type 2 diabetes, we hypothesised that peripheral monocytes in these patients,
exposed to these factors in vivo, would demonstrate increased MMP production compared to
controls.
Methods: We examined peripheral venous monocyte expression of MMP and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in 18 controls and 22 subjects with Type 2 diabetes and no previous
cardiovascular complications.
Results: No significant difference in MMP-1, 3 or 9 or TIMP-1 production was observed between
control and diabetes groups.
Conclusions: Monocyte MMP-1, 3, and 9, and TIMP-1, production are not abnormal in Type 2
diabetes. This data cannot be extrapolated to monocyte – macrophage behaviour in the vessel wall,
but it does suggest MMP and TIMP-1 expression prior to monocyte infiltration and transformation
are not abnormal in Type 2 diabetes.
Background
The risk of an acute coronary syndrome is dependent on
the stability of the atheromatous coronary plaque, and
plaque stability and rupture may be mediated by focal
over-expression in the plaque of matrix metalloproteinas-
es or MMPs [1]. The MMPs are a family of proteinases ca-
pable of degrading all extracellular matrix (ECM)
components and whose activity is tightly controlled by
endogenous inhibitors known as tissue inhibitors of met-
alloproteinases or TIMPs [2]. The expression of a number
of MMPs are up-regulated in atherosclerotic plaques ; in
particular MMPs-1, -3, -7 and -9 have been localised to re-
gions of macrophage – derived foam cell accumulation in
the vulnerable plaque shoulders where rupture often oc-
curs [3,4]. Type 2 diabetes is associated with a substantial-
ly increased risk of an acute coronary event [5], and is
characterised by abnormalities in a number of factors that
could modulate the expression of monocyte-derived
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MMPs such as plasma tumour necrosis factor-alpha (TNF-
α) [6,7], modified lipoproteins [8,9], hyperglycaemia and
changes in oxidative balance [10]. Atherosclerotic plaque
foam cells are mainly derived from infiltrating peripheral
monocytes that have differentiated into macrophages dur-
ing extravasation and taken up lipoproteins via newly ex-
pressed scavenger receptors such as CD36 but there is no
available adequate data on monocyte or macrophage
MMP or TIMP expression in Type 2 diabetes [11]. We hy-
pothesised that monocytes derived from subjects with
Type 2 diabetes might demonstrate altered MMP produc-
tion due to exposure to such factors in vivo.
Methods
Subjects
Subjects with Type 2 diabetes and without known coro-
nary artery disease (n = 22) were recruited from the Elsie
Bertram Diabetes Centre, Norwich if they had Type 2 dia-
betes based on the American Diabetes Association criteria
[12] and no clinical or electrocardiographic evidence of is-
chaemic heart disease. Coronary angiography or stress
testing were not undertaken as part of this protocol, but
patients with a history of previous confirmed myocardial
infarction, or 12 – lead or exercise electrocardiogram evi-
dence of myocardial infarction or ischaemic heart disease
were excluded. Controls without Type 2 diabetes (n = 18)
had no clinical history or electrocardiographic evidence of
vascular disease, and all had a fasting plasma glucose be-
low 6.1 mmol/l [12] and no patient with impaired fasting
glucose was included in the control or diabetes group. No
patient or control was taking aspirin or lipid lowering
therapy. No subjects with Type 2 diabetes had macropro-
teinuria or microalbuminuria as determined by an elevat-
ed early morning albumin : creatinine ratio, and active
smokers or subjects taking insulin were excluded. Thirteen
of the 22 patients with Type 2 diabetes were taking a
sulphonylurea (either alone in combination), of whom 7
were taking gliclazide. No patient was taking rosiglitazone
or pioglitazone.
Primary human monocyte isolation
Monocytes were purified from plasma by density gradient
centrifugation after collection of peripheral blood into
EDTA-containing tubes as previously described [13].
Monocyte purity was greater than 85% and cell viability
(assessed by trypan blue exclusion) was normally greater
than 95% [13].
Monocyte culture
The monocytes were resuspended in RPMI 1640 medium
(Gibco) containing 25 mmol/L glucose, 2 mmol/L L-
glutamine, 1 mmol/L sodium pyruvate, non-essential
amino acids, penicillin, streptomycin. Polymixin B was
also included in the medium to avoid possible stimula-
tion by endotoxin. The cells were cultured in duplicate for
48 hours, 37°C, 5% CO2, at a density of 250 000/well of
24-well tissue culture dish (Costar) in a total volume of
0.5 ml. After 48 hours cell viability was assessed by meas-
uring lactate dehydrogenase release using a cytotoxicity
detection kit (Boehringer-Mannheim). Cell viability at the
end of the culture period was normally 70%. Conditioned
media was collected, centrifuged to remove cell debris and
frozen at -20°C.
MMP analysis
Total MMP-3, total TIMP-1, pro-and complexed MMP-9
levels in monocyte conditioned media were measured us-
ing the Biotrak human ELISA systems (Amersham Phar-
macia Biotech UK) according to the manufacturers
instructions. Total MMP-1 was assessed using an in-house
double antibody sandwich ELISA employing the mono-
clonal capture antibody RRU-CL1 and a biotinylated pol-
yclonal anticollagenase IgG [14]. To detect the conversion
of pro-to active MMP-9 gelatin zymography was carried
out as previously described [15]. Conditioned media di-
luted in non-reducing sample buffer was subjected to
SDS-PAGE on 10% (w/v) polyacrylamide gels incorporat-
ing 0.1% (w/v) gelatin. After electrophoresis the gel was
washed in 2 × 15 minute washes of 2.5% (v/v) Triton X-
100 followed by overnight incubation at room tempera-
ture in 50 mM Tris, pH 7.5, 0.2 M NaCl, 10 mM CaCl2.
The gel was stained with 0.25% (w/v) Coomassie blue R-
250, 50% (v/v) methanol, 10% (v/v) acetic acid, and
destained in 30% (v/v) methanol, 1% (v/v) acetic acid.
Enzyme activity appeared as cleared bands where the sub-
strate had been degraded.
Statistical analysis
Data for MMP-1, MMP-3, MMP-9 and TIMP-1 were not
normally distributed and are expressed as a median with
interquartile range. Differences between groups were ana-
lysed by two-tailed Mann-Whitney U tests. Relationships
between variables were assessed using simple linear re-
gression. < 0.05 was taken as significant.
Although no available data is available to allow definitive
power calculations, sample sizes were selected to offer
more than 80 % power at the 5 % level to detect one
standard deviation difference between group means as-
suming normal and equal variance between groups.
Results
Clinical features (Table 1)
Clinical features of the groups are shown in Table 1.
Basal monocyte MMP expression (Table 1)
MMP-9 and TIMP-1 were abundantly expressed in the cul-
tured primary human monocytes when compared to
MMP-1, and MMP-3, production was negligible (median
0.0 ng/ml). Using gelatin zymography it was shown thatCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/3
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MMP-9 was expressed in the proform and little active en-
zyme was found (not shown). MMP-2 was not found in
any sample (not shown). In the diabetes group, there was
no significant difference in MMP-9 or TIMP-1 expression
between those who were treated with diet and those re-
ceiving oral agents (p > 0.5 for both MMP-9 and TIMP-1),
or between those taking gliclazide or other sulphonylure-
as (p > 0.5 for both MMP-9 and TIMP-1).
Comparison between groups (Table 1)
Basal median monocyte MMP-1, MMP-3, MMP-9 and
TIMP-1 expression did not differ significantly between
controls and Type 2 diabetes groups. Age, fasting plasma
glucose and HbA1c were not significantly related to MMP
or TIMP-1 production in either group (all p > 0.1)
Discussion
The main finding of this study is that peripheral venous
monocytes from patients with Type 2 diabetes and with-
out clinical coronary artery disease do not differ in MMP-
9, MMP-3, MMP-1 or TIMP-1 expression compared to
controls. Type 2 diabetes is associated with abnormalities
in a number of variables that influence MMP expression
in vitro [7,10], but in vivo monocyte MMP and TIMP-1 ex-
pression do not appear to be abnormal in Type 2 diabetes.
There is surprisingly little data on MMP or TIMP expres-
sion in human Type 2 diabetes, despite the great interest
in the MMP system and coronary plaque stability. In-
creased MMP-9 expression in vascular tissue and plasma
of animal models of diabetes [16] has been described, and
vascular endothelial cells express more MMP-9 in condi-
tions of high glucose in vitro [16], and wound fluid and
ulcer punch biopsies derived from diabetes subjects show
increased expression of MMP-2, MMP-1 and MMP-8 and
conflicting results for MMP-9 [17,18]. However, other
groups have described down regulation of an MMP induc-
tion and activation system in internal mammary arteries
derived from subjects with diabetes [19]. Elevated plasma
levels of MMP-9 are a feature of Type 2 diabetes with
microabuminuria [20], and in Type 1 patients [21] al-
though it is unclear what relevance plasma MMP concen-
trations have to any tissue biological process. None of the
diabetes subjects in this study were taking aspirin or HMG
Co A reductase inhibitors which could have influenced
MMP expression [22,23], and although gliclazide may
have some antioxidant properties [24], the Type 2 diabe-
tes patients taking gliclazide did not differ significantly in
MMP or TIMP expression from those taking no or other
medication. It is necessary to stress that these observations
were made in Type 2 diabetes patients in good glycaemic
control and without clinically expressed coronary artery
disease, and it is unknown if monocyte MMP or TIMP ex-
pression is different in Type 2 patients with poor control
or established vascular disease.
The results from this study cannot be extended to macro-
phage MMP expression within the coronary plaque or ves-
sel wall after monocyte – macrophage transformation, but
it does suggest basal monocyte MMP and TIMP-1 expres-
Table 1: Clinical features, monocyte matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinases (TIMP) 
expression in controls and in Type 2 diabetes patients
Control DM CVD-
n1 8 2 2
Age (yrs) 51.7 (8) 56.0 (8) *
Male : Female 14:4 16:6
Diabetes duration (yrs) N/A 6.5 (5.9)
BMI (kg/m2) 26.6 (6.0) 27.4 (7.2)
HbA1c (%) 5.1 (0.4) 7.0 (1.4) **
Fasting plasma glucose (mmol/l) 4.7 (0.7) 8.6 (2.9) **
Treatment
Aspirin 0 0
Statin 0 0
Diet alone - 6
Sulphonylurea alone - 8
Metformin alone - 3
Combination - 5
MMP-1 (ng/ml) 5.5 (5) 6.4 (5.9)
MMP-3 (ng/ml) 0.0 (1.2) 0.0 (0.8)
MMP-9 (ng/ml) 42.1 (82) 48.2 (51)
TIMP-1 (ng/ml) 192.9 (108) 163.0 (111)
* p < 0.05 compared to controls ** p < 0.0001 compared to controls. Clinical data shown as mean (SD), MMP and TIMP-1 data shown as median 
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sion prior to monocyte infiltration and transformation are
not abnormal in Type 2 diabetes.
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